Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Merus N.V.
DescriptionBispecific IgG antibody targeting programmed cell death 1 (PD-1; PDCD1; CD279) and T cell immunoglobulin and mucin domain 3 (TIM3; HAVCR2)
Molecular Target Programmed cell death 1 (PD-1) (PDCD1) (CD279) ; T cell immunoglobulin and mucin domain 3 (TIM3) (HAVCR2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentDiscovery
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today